Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists

Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain’s natural systems for maintaining alertness and sleep stability.

Eli Lilly and Company (NYSE:LLY) plans to urgently utilize Centessa’s clinical portfolio to address the profound and life-altering impacts of sleep disruption. By integrating these assets, the company seeks to explore the orexin system’s broader potential for brain health and provide solutions for significant unmet needs in neuroscience.

Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists

This acquisition aligns with Eli Lilly’s ongoing focus on pioneering life-changing discoveries across various health challenges, including diabetes, obesity, Alzheimer’s, and immunology. The company remains committed to advancing innovative medical solutions and ensuring their accessibility for patients worldwide.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1